Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Alasdair R Fraser"'
Autor:
Catriona Graham, John F Dillon, Scott Semple, Neil Lachlan, Alasdair R Fraser, Jonathan Andrew Fallowfield, Francesca Moroni, Mark Macmillan, Thomas Manship, Stuart J Forbes, Paul Noel Brennan, Alison Glover, David M Morris, Chloe Pass, Neil W A McGowan, Marc L Turner, John D M Campbell
Publikováno v:
BMJ Open, Vol 11, Iss 11 (2021)
Introduction Liver cirrhosis is a growing global healthcare challenge. Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and complications related to portal hypertension. There are no licensed antifibrotic or proregenerative medi
Externí odkaz:
https://doaj.org/article/89f7b18180ca494fa34b4ea6b54326f8
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/ec4f2c56203b40a4851fdc6718e8999b
Autor:
Rachel S. Cooper, Catherine Sutherland, Linda M. Smith, Graeme Cowan, Mark Barnett, Donna Mitchell, Colin McLean, Stuart Imlach, Alan Hayes, Sharon Zahra, Champa Manchanayake, Mark A. Vickers, Gerry Graham, Neil W. A. McGowan, Marc L. Turner, John D. M. Campbell, Alasdair R. Fraser
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Adoptive immunotherapy with Epstein–Barr virus (EBV)-specific T cells is an effective treatment for relapsed or refractory EBV-induced post-transplant lymphoproliferative disorders (PTLD) with overall survival rates of up to 69%. EBV-specific T cel
Externí odkaz:
https://doaj.org/article/0cb45f6c1180476fa75a74a1fdc66481
Publikováno v:
Frontiers in Lab on a Chip Technologies, Vol 3 (2024)
Microfluidic devices are useful tools for a wide range of biomedical, industrial, and environmental applications. Hybrid microfluidic devices utilising more than two materials are increasingly being used for their capacity to produce unique structure
Externí odkaz:
https://doaj.org/article/3184a313979f4325b43c7276ebde8e33
Autor:
Thomas Manship, Mark T. Macmillan, Francesca Moroni, John M. Campbell, Paul Noel Brennan, Alison Glover, Alasdair R. Fraser, John F. Dillon, Stuart J. Forbes, Neil W. A. McGowan, Neil Lachlan, David M. Morris, Marc Turner, Chloe Pass, Jonathan A. Fallowfield, Catriona Graham, Scott Semple
Publikováno v:
BMJ Open, Vol 11, Iss 11 (2021)
BMJ Open
Brennan, P N, MacMillan, M, Manship, T, Moroni, F, Glover, A, Graham, C, Semple, S, Morris, D M, Fraser, A R, Pass, C, McGowan, N W A, Turner, M L, Lachlan, N, Dillon, J F, Campbell, J D M, Fallowfield, J A & Forbes, S J 2021, ' Study Protocol: A multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH) ', BMJ Open . https://doi.org/DOI: 10.1136/bmjopen-2021-053190
BMJ Open
Brennan, P N, MacMillan, M, Manship, T, Moroni, F, Glover, A, Graham, C, Semple, S, Morris, D M, Fraser, A R, Pass, C, McGowan, N W A, Turner, M L, Lachlan, N, Dillon, J F, Campbell, J D M, Fallowfield, J A & Forbes, S J 2021, ' Study Protocol: A multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH) ', BMJ Open . https://doi.org/DOI: 10.1136/bmjopen-2021-053190
IntroductionLiver cirrhosis is a growing global healthcare challenge. Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and complications related to portal hypertension. There are no licensed antifibrotic or proregenerative medic
Autor:
John Drain, Marc Turner, Kanna Ramaesh, Coral MacRury, Alison Glover, Neil W. A. McGowan, Ian Downing, Jane Pelly, Sanjay Mantry, Louis Nerurkar, Jacqueline Barry, Ashish Agrawal, Alasdair R. Fraser, Baljean Dhillon, Stephen B. Kaye, B. Cuthbertson, Emily Hargreaves, John D.M. Campbell, Anne P.M. Atkinson, Sajjad Ahmad, Carol Bienek, Margaret MacDonald
Publikováno v:
Stem Cells Translational Medicine
STEM CELLS TRANSLATIONAL MEDICINE
STEM CELLS TRANSLATIONAL MEDICINE
Limbal stem cell deficiency (LSCD) is a disease resulting from the loss or dysfunction of epithelial stem cells, which seriously impairs sight. Autologous limbal stem cell transplantation is effective in unilateral or partial bilateral disease but no
Autor:
John M. Hallett, Sofia Ferreira-Gonzalez, Tak Yung Man, Alastair M. Kilpatrick, Hannah Esser, Kayleigh Thirlwell, Mark T. Macmillan, Daniel Rodrigo-Torres, Benjamin J. Dwyer, Victoria L. Gadd, Candice Ashmore-Harris, Wei-Yu Lu, John P. Thomson, Maurits A. Jansen, Eoghan O’Duibhir, Philip J. Starkey Lewis, Lara Campana, Rhona E. Aird, Thomas S.R. Bate, Alasdair R. Fraser, John D.M. Campbell, Gabriel C. Oniscu, David C. Hay, Anthony Callanan, Stuart J. Forbes
Publikováno v:
Hallett, J, Ferreira-Gonzalez, S, Man, J, Kilpatrick, A, Esser, H, Thirwell, K, Macmillan, M, Rodrigo Torres, D, Dwyer, B, Gadd, V, Ashmore-Harris, C, Lu, W-Y, Thomson, J, Jansen, M, O'Duibhir, E, Starkey Lewis, P, Campana, L, Aird, R, Bate, T, Fraser, A R, Campbell, J D M, Oniscu, G C, Hay, D C, Callanan, A & Forbes, S J 2022, ' Human biliary epithelial cells from discarded donor livers rescue bile duct structure and function in a mouse model of biliary disease ', Cell Stem Cell . https://doi.org/10.1016/j.stem.2022.02.006
Biliary diseases can cause inflammation, fibrosis, bile duct destruction, and eventually liver failure. There are no curative treatments for biliary disease except for liver transplantation. New therapies are urgently required. We have therefore puri
Autor:
Marc Turner, John D.M. Campbell, Paul Burgoyne, Stuart N. Imlach, Sharon Zahra, Lisa Jarvis, Linda Smith, Rachel S Cooper, David M. Turner, Alasdair R. Fraser
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology
Frontiers in Immunology
COVID-19 disease caused by the SARS-CoV-2 virus is characterized by dysregulation of effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be corrected by adoptive cellular therapy using donor-derived virus-specific
Autor:
Gwen Wilkie, Rachel S Cooper, Mark A. Vickers, Alasdair R. Fraser, John D.M. Campbell, Aleksandra Kowalczuk, Marc Turner
Publikováno v:
Clinical and Experimental Immunology
Adoptive immunotherapy using Epstein–Barr Virus (EBV)‐specific T cells is a potentially curative treatment for patients with EBV‐related malignancies where other clinical options have proved ineffective. We describe improved good manufacturing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01cd648443142e6cf2afbe5a41fe790
https://doi.org/10.22541/au.161002473.32537816/v1
https://doi.org/10.22541/au.161002473.32537816/v1
Autor:
Sharon Zahra, John D.M. Campbell, Alasdair R. Fraser, Lisa Jarvis, Rachel S Cooper, Paul Burgoyne, Stuart N. Imlach, Marc Turner, Linda Smith
COVID-19 disease caused by the SARS-CoV-2 virus is characterized by dysregulation of effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be corrected by adoptive cellular therapy using donor-derived virus-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c77a3f1e0ce44a4e7fc7e881a0184e80
https://doi.org/10.1101/2020.08.05.237867
https://doi.org/10.1101/2020.08.05.237867